Cancer immunotherapies targeting immune checkpoints, such as CTLA4 and the PD-1/PD-L1 axis, have presented substantial clinical benefits for various cancer types, such as melanoma, leukemia, and lung cancer [81,82]. This evidence concerns the gene CTLA4 and cancer.